| Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia CD DiNardo, K Pratz, V Pullarkat, BA Jonas, M Arellano, PS Becker, ... Blood, The Journal of the American Society of Hematology 133 (1), 7-17, 2019 | 1631 | 2019 |
| Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label … CD DiNardo, KW Pratz, A Letai, BA Jonas, AH Wei, M Thirman, ... The lancet oncology 19 (2), 216-228, 2018 | 697 | 2018 |
| Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study AH Wei, SA Strickland Jr, JZ Hou, W Fiedler, TL Lin, RB Walter, A Enjeti, ... Journal of Clinical Oncology 37 (15), 1277-1284, 2019 | 638 | 2019 |
| Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma RV Shaji Kumar, Jonathan L. Kaufman, Cristina Gasparetto, Joseph Mikhael Blood, blood-2017-06-788786, 2017 | 514* | 2017 |
| Statins enhance efficacy of venetoclax in blood cancers D 1. Lee, S., Roberts, Juzrez, D., Vo, T., Bhatt, S., Herzog, L., Mallya, S ... Science Translational Medicine 10 (455), eaaq 1240, 2018 | 80 | 2018 |
| Phase 1/2 study of venetoclax with low-dose cytarabine in treatment-naive, elderly patients with acute myeloid leukemia unfit for intensive chemotherapy: 1-year outcomes A Wei, SA Strickland, GJ Roboz, JZ Hou, W Fiedler, TL Lin, RB Walter, ... Blood 130, 890, 2017 | 76 | 2017 |
| Venetoclax in combination with hypomethylating agents induces rapid, deep, and durable responses in patients with AML ineligible for intensive therapy DA Pollyea, KW Pratz, BA Jonas, A Letai, VA Pullarkat, A Wei, ... Blood 132, 285, 2018 | 46 | 2018 |
| Venetoclax Monotherapy for Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results from a Phase I Study CG Shaji Kumar, Ravi Vij, Jonathan L. Kaufman, Joseph Mikhael, Thierry Facon ... Blood 128 (22), 488, 2016 | 46* | 2016 |
| Venetoclax with low-dose cytarabine induces rapid, deep, and durable responses in previously untreated older adults with AML ineligible for intensive chemotherapy A Wei, SA Strickland, JZ Hou, W Fiedler, TL Lin, RB Walter, AK Enjeti, ... Blood 132, 284, 2018 | 42 | 2018 |
| Flexible combination of multiple diagnostic biomarkers to improve diagnostic accuracy T Xu, Y Fang, A Rong, J Wang BMC Medical Research Methodology 15 (94), 2015 | 37 | 2015 |
| Statistical inference for two-regime stochastic car-following models T Xu, J Laval Transportation Research Part B: Methodological 134, 210-228, 2020 | 33 | 2020 |
| Minimum clinically important difference in medical studies AS Hedayat, J Wang, T Xu Biometrics 71 (1), 33-41, 2015 | 33 | 2015 |
| Updated safety and efficacy of venetoclax with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia CD DiNardo, DA Pollyea, BA Jonas, M Konopleva, V Pullarkat, A Wei, ... Blood 130, 2628, 2017 | 31 | 2017 |
| Comparing Logistic Regression, Support Vector Machines and Permanental Classification Methods in Predicting Hy-pertension HH Huang, T Xu, J Yang BMC Proceedings 8 (Suppl 1), S96, 2014 | 31 | 2014 |
| Analysis of a two-regime stochastic car-following model: Explaining capacity drop and oscillation instabilities T Xu, JA Laval Transportation Research Record 2673 (10), 610-619, 2019 | 25 | 2019 |
| A model-free estimation for the covariate-adjusted Youden index and its associated cut-point T Xu, J Wang, Y Fang Statistics in Medicine 33 (28), 4963–4974, 2014 | 23 | 2014 |
| SAFETY AND EFFICACY OF VENETOCLAX (VEN) IN COMBINATION WITH DECITABINE OR AZACITIDINE IN TREATMENT-NAIVE, ELDERLY PATIENTS (>= 65 YEARS) WITH ACUTE MYELOID LEUKEMIA (AML) K Pratz, DA Pollyea, BA Jonas, V Pullarkat, A Wei, M Arellano, PS Becker, ... Haematologica 102, 175-176, 2017 | 18 | 2017 |
| Durable Response with Venetoclax in Combination with Decitabine or Azacitidine in Elderly Patients with Acute Myeloid Leukemia CD DiNardo | 15 | 2018 |
| Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR: A Phase 2 Placebo … M Stahl, J Roehmel, M Eichinger, F Doellinger, L Naehrlich, MV Kopp, ... Annals of the American Thoracic Society 20 (8), 1144-1155, 2023 | 10 | 2023 |
| Phase 3, randomized, double-blind, placebo-controlled study of venetoclax combined with azacitidine versus azacitidine in treatment-naïve patients with acute myeloid leukemia J Potluri, T Xu, WJ Hong, MH Mabry Journal of Clinical Oncology 35, 2017 | 9 | 2017 |
Suresh Kumar Agarwal, MS, PhD, RPHDirector, Clincal PharmacologyVerified email at bmrn.com
